Lipoprotein (a)
Label Mnemonic: LIPOA
Epic Lab Code: LAB3510
Downtime Form: A-1a Miscellaneous Request
Commercial Mail-out Laboratory
5231 RCP
356-8593
Specimen(s):
Serum
Specimen Instructions:
Suggest fasting for 8 hours.
Collection Medium:
Red top tube 5 mL (Clot Activator)
Minimum:
0.4 mL serum
Turn Around Time:
4 days upon receipt at reference laboratory (not reported on Saturday or Sunday).
Reference Range:
Lp(a) CHOLESTEROL
Normal: <3 mg/dL
Suggests increased risk of coronary artery disease: > or =3 mg/dL

LpX
Undetectable
Interpretive Data:
Patients with increased Lp(a) cholesterol values have an approximate 2- fold increased risk for developing cardiovascular disease and events.
Comments:
Useful For:
Evaluation of increased risk for cardiovascular disease and events:
-Most appropriately measured in individuals at intermediate risk for cardiovascular disease according to the individuals' Framingham risk score

-Patients with early atherosclerosis or strong family history of early atherosclerosis without explanation by traditional risk factors should also be considered for testing


Cautions:
Lp(a) cholesterol values should not be confused with Lp(a) mass values, although they are highly correlated. Lp(a) cholesterol values will be approximately 10X lower than Lp(a) mass values, but the difference between the measures is not uniform. Lp(a) mass values are considered elevated when >30 mg/dL. Lp(a) cholesterol is increased if > or =3 mg/dL.


Clinical Information:
Lipoprotein (a) (Lp[a]) is a highly heterogeneous molecule, consisting of a low-density lipoprotein (LDL) with a highly glycosylated apolipoprotein(a) (apo[a]) covalently linked to the apolipoprotein B moiety of LDL via a single disulfate bond. Lp(a) has been associated with atherogenesis and promotion of thrombosis. Increased levels of Lp (a) have been estimated to confer a 1.5 to 3.0-fold increased risk for coronary artery disease (CAD) in many but not all studies. Apo(a) has approximately 80% structural homology with plasminogen, but does not contain the active site for fibrin cleavage. One proposed mechanism for Lp(a)'s atherogenicity is competition for binding sites with plasminogen during fibrin clot formation and the resulting inhibition of fibrinolysis. Recently a high correlation was demonstrated between Lp (a) and oxidized LDL, suggesting that the atherogenicity of Lp(a) lipoprotein may be mediated in part by associated proinflammatory oxidized phospholipids.

Lack of standardization of assays and apo(a) heterogeneity may partially account for these discrepancies. The heterogeneity of Lp(a) arises mainly from the variable number of kringle repeats in the apo(a) portion of the molecule. Kringles are specific structural domains containing 3 intra-strand disulfide bonds that are highly homologous to similar repeats found in plasminogen.

In the clinical laboratory, immunologic methods are generally used to quantify Lp(a) protein mass. Reagents for Lp(a) mass measurement are available from multiple manufacturers and although standardization efforts are underway, currently available methods are not standardized. Difficulties in standardizing Lp(a) mass measurement arise from the variability in signals produced by different reagents due to the size polymorphisms of apo(a). For this reason, some elevations of Lp(a) mass are associated with low levels of Lp(a) cholesterol. Lp(a) quantification can be done by densitometric measurement of Lp(a) cholesterol. This method measures only the cholesterol contained in the Lp(a) particles and is thus not influenced by the relative size of the apo(a) size, it may provide a more specific assessment of cardiovascular risk than Lp(a) mass measurement. Lp(a) cholesterol measurement may be used in concert with Lp(a) mass determination, or may be used as a stand-alone test for assessment of risk.
Methodology:
Electrophoresis, Enzyme Staining, and Densitometry
CPT Code:
83700